<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Opioid use disorder: Pharmacologic management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Opioid use disorder: Pharmacologic management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Opioid use disorder: Pharmacologic management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Strain, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew J Saxon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H19508580"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Opioids, used medically for pain relief, have analgesic and central nervous system depressant effects, as well as the potential to cause euphoria. Opioid use disorder (OUD) can be related to misuse of pharmaceutical opioids, heroin, or other opioids such as <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> and its analogs. OUD is typically a chronic, relapsing illness, associated with significantly increased rates of morbidity and mortality.</p><p>Medication for OUD (MOUD) consists of treatment with an opioid agonist or antagonist and is first-line treatment for most patients with an OUD. MOUD appears to reinforce abstinence and improve treatment retention [<a href="#rid1">1-4</a>]. Our approach to treating OUD, including choice of treatment, is discussed elsewhere. Pharmacotherapy for OUD is reviewed here. The epidemiology, clinical manifestations, course, screening, assessment, diagnosis, and psychosocial treatment for OUD are reviewed separately. Other topics including those addressing medically supervised opioid withdrawal, prescription drug misuse, substance use disorder in clinicians, management of OUD during pregnancy, and treatment of acute pain in the patient chronically using opioids are also discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/108803.html" rel="external">"Opioid use disorder: Treatment overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/99647.html" rel="external">"Opioid use disorder: Psychosocial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7808.html" rel="external">"Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7806.html" rel="external">"Substance use disorders in physicians: Epidemiology, clinical manifestations, identification, and engagement"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/93398.html" rel="external">"Substance use disorders in physicians: Assessment and treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy"</a>.)</p><p></p><p class="headingAnchor" id="H4039987952"><span class="h1">APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>Our preference is to treat all individuals with opioid use disorder (OUD) with medication for OUD (MOUD) and psychotherapy. We consider OUD to be a chronic condition and treat indefinitely. However, in individuals who are fully free of problematic substance use, are engaged in productive activities, and have stable psychosocial support for at least 6 to 12 months, we support a slow taper off of MOUD at the patient’s request. The general approach to selecting treatment for OUD, including selecting among MOUD options, is described separately  (<a class="graphic graphic_algorithm graphicRef134961" href="/d/graphic/134961.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/108803.html" rel="external">"Opioid use disorder: Treatment overview", section on 'Assessment of response'</a> and  <a class="medical medical_review" href="/d/html/108803.html" rel="external">"Opioid use disorder: Treatment overview", section on 'Duration of therapy for responders'</a>.)</p><p class="headingAnchor" id="H1051259911"><span class="h1">BUPRENORPHINE: OPIOID AGONIST</span><span class="headingEndMark"> — </span>In individuals with an opioid use disorder (OUD), <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> suppresses withdrawal symptoms, craving, and blocks the effect of other opioids thereby reducing use [<a href="#rid1">1,5,6</a>]. As a partial agonist with high affinity for mu-opioid receptor it displaces other agonists from the receptor (high affinity) potentially precipitating withdrawal (partial agonist) in individuals on opioids. Although individuals treated with buprenorphine are physically dependent upon the medications, they do not typically have the pattern and severity of problematic behaviors associated with use and misuse of heroin or pharmaceutical opioids including <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> [<a href="#rid7">7-9</a>].</p><p class="headingAnchor" id="H3807189453"><span class="h2">Choosing among buprenorphine formulations</span><span class="headingEndMark"> — </span>For most individuals, our initial choice of opioid agonist for the treatment of OUD is with transmucosal <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>. However, we prefer to use longer-acting formulations of buprenorphine in individuals with limited adherence, misuse, and/or diversion of transmucosal buprenorphine. We consider patient preference and use shared decision-making in formulating the treatment plan. (See  <a class="medical medical_review" href="/d/html/108803.html" rel="external">"Opioid use disorder: Treatment overview", section on 'Shared decision-making'</a>.)</p><p><a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">Buprenorphine</a> is available in daily transmucosal formulations, as an extended-release subcutaneous injection (Sublocade; given every 30 days) that requires an initial period of transmucosal buprenorphine, and as a weekly or monthly subcutaneous injectable formulation (Brixadi) that can be used without a period of transmucosal stabilization. </p><p class="headingAnchor" id="H2901315746"><span class="h2">Transmucosal formulations</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">Buprenorphine</a> is most commonly administered transmucosally (film strip or tablet) in a combination preparation with <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a>, an opioid antagonist. The combination is used to prevent individuals from crushing the tablets and dissolving them for intravenous injection or dissolving the soluble film for injection [<a href="#rid10">10</a>]. Naloxone has little to no bioavailability or activity when administered sublingually but discourages intravenous buprenorphine misuse since the naloxone can precipitate withdrawal when given parenterally to individuals with physiologic dependence on opioids. The ratio of buprenorphine to naloxone is 4:1, and a variety of dose sizes are available (eg, 2/0.5, 4/1, 8/2, 12/3). Additionally, a sublingual tablet form of buprenorphine/naloxone provides equivalent amounts of the medication as the traditional tablet doses used, but contains a lower dose of buprenorphine. (For example, one of the formulations provides 5.7 mg dose that is equal to 8 mg of buprenorphine.)</p><p>A transmucosal formulation of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> that does not contain <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> is also available. Although allergy to naloxone is extremely rare, some individuals report an allergy. Additionally, some individuals report unpleasant side effects from the combination formulation that they do not get from the buprenorphine only formulation. This may be due to trace amounts of naloxone that may be absorbed transmucosally [<a href="#rid11">11,12</a>]. In those rare cases, a shared decision-making discussion is needed to decide on the formulation to use. We determine whether to use the non-naloxone formulation on a case-by-case basis.</p><p class="headingAnchor" id="H778994298"><span class="h3">Standard induction</span><span class="headingEndMark"> — </span>We use a standard induction in most clinical scenarios. However, in some cases, for example, if the individual presents and is not in early withdrawal or for high levels of physiologic dependence, we often use another protocol, such as low-dose initiation. (See <a class="local">'Alternative induction methods for specific circumstances'</a> below.)</p><p class="headingAnchor" id="H3718535698"><span class="h4">Timing and site of initiation</span><span class="headingEndMark"> — </span>When initiating <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, the individual needs to be abstinent from other opioids long enough to enter a state of mild withdrawal (see <a class="local">'Assessing for withdrawal'</a> below). Time to reach this state varies as a function of the half-life of the opioid being used by the patient. As examples, withdrawal from heroin or other short-acting opioids can appear 6 to 12 hours after the last dose, while withdrawal from <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> can appear in 24 to 36 hours.</p><p>Induction can be done in the office, emergency department, or at home. When done in the office or emergency department, the <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> is given directly to the patient after assessment for withdrawal. The patient is then given supply of several days lasting until scheduled follow-up appointment. When done at home, the patient receives two to seven days of medication depending upon the patient’s circumstances and scheduling of follow-up appointments and is instructed on how to assess for withdrawal. (See <a class="local">'Assessing for withdrawal'</a> below and  <a class="medical medical_review" href="/d/html/300.html" rel="external">"Acute opioid intoxication in adults", section on 'Prevention of recurrent opioid overdose'</a>.)</p><p class="headingAnchor" id="H1471858465"><span class="h4">Assessing for withdrawal</span><span class="headingEndMark"> — </span>To determine that the patient has entered a state of mild to moderate opioid withdrawal, we observe the patient for early signs of opioid withdrawal such as sweating, tremor, piloerection, irritability, or yawning at the time of initiation. We use a standard measure, the Clinical Opiate Withdrawal Scale (COWS)  (<a class="graphic graphic_table graphicRef106994" href="/d/graphic/106994.html" rel="external">table 1</a>). We consider a score of 12 or more on the COWS to be objective evidence of mild to moderate withdrawal. When signs of early withdrawal appear, we begin the induction with <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>. Buprenorphine ameliorates the withdrawal by binding to and activating the mu-opioid receptors [<a href="#rid10">10</a>].</p><p>If home induction is planned, we instruct the patient how to determine the presence of sufficient withdrawal to begin induction. We review the objective signs of withdrawal (tremor, piloerection, sweating) and how to differentiate them from subjective symptoms (eg, irritability, restlessness). We often ask the patient to use the Subjective Opiate Withdrawal Scale as a guide to whether they are in mild to moderate withdrawal and whether to begin induction. Scores of 17 or greater indicate that there is a mild to moderate level of withdrawal and that induction can start. Tools and handouts for patients and family members that can be helpful in home inductions can be found in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpcssnow.org%2Fclinical-tools%2F&amp;token=fCrgfzN7pYf%2FbgtkU9ShI2L5WevFbBUw5L3hldHzjAbHBXeYDrU7ZEA0tfJlwhFq&amp;TOPIC_ID=7803" target="_blank">Providers Clinical Support System</a>. (See  <a class="medical medical_review" href="/d/html/7808.html" rel="external">"Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder", section on 'Monitoring'</a>.)</p><p class="headingAnchor" id="H2323767689"><span class="h4">Initiating induction</span><span class="headingEndMark"> — </span>Induction begins with the individual manifesting signs of withdrawal. (See <a class="local">'Standard induction'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Day 1</strong> – We typically start transmucosal <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> at a dose of 4 mg (ie, 4 mg/1 mg of <a class="drug drug_general" data-topicid="8788" href="/d/drug information/8788.html" rel="external">buprenorphine-naloxone</a>). Relief of symptoms may occur in minutes although one to two hours of observation is needed for full effect. We observe the patient for a full two hours. At that time, we reassess for symptoms of withdrawal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If withdrawal symptoms persist (eg, COWS ≥6  (<a class="graphic graphic_table graphicRef106994" href="/d/graphic/106994.html" rel="external">table 1</a>)), an additional dose of up to 4 mg can be administered.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the individual has sufficient relief of symptoms (COWS &lt;6) we allow the individual to go home. We provide a second dose of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> for the individual to bring home and take if withdrawal symptoms or craving become prominent before the next morning.</p><p></p><p class="bulletIndent1">Federal guidelines recommend a maximum dose of 8 mg (ie, 8/2 mg) on the first day. In some cases, for example if the individual has been using <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>, higher doses may be needed [<a href="#rid13">13</a>].<strong> </strong>Thus, a dose higher than 8 mg can be considered on the first day, although this is generally the exception rather than the rule. Further dose increases can occur on subsequent days, as noted below.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Day 2 </strong>– The patient is given a single dose consisting of the total of the doses received the first day. We monitor the individual over the next one to two hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If residual symptoms are present (ie, COWS ≥6  (<a class="graphic graphic_table graphicRef106994" href="/d/graphic/106994.html" rel="external">table 1</a>)), we give another 4 mg (ie, 4 mg/2 mg). We continue to monitor and give 4 mg every two hours depending on COWS score (ie, COWS score ≥6). We give a maximum total dose of 16 mg (ie, 16/4 mg <a class="drug drug_general" data-topicid="8788" href="/d/drug information/8788.html" rel="external">buprenorphine-naloxone</a>) on day 2.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the individual has sufficient relief of symptoms (COWS &lt;6) we allow the individual to go home and provide further maintenance doses. We typically give patients a week supply, but the precise number of days of medication given varies depending upon the patient and their circumstances (eg, social supports at home).</p><p></p><p class="bulletIndent1">United States federal and European guidelines recommend a maximum dose on day 2 of 16 mg total (ie, 16/4 mg of <a class="drug drug_general" data-topicid="8788" href="/d/drug information/8788.html" rel="external">buprenorphine-naloxone</a>) [<a href="#rid13">13,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance</strong> – We usually do not increase the dose above 16 mg for several days to one week to allow pharmacologic steady state to be reached. Most individuals will stabilize on 8 to 16 mg/day of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> [<a href="#rid15">15</a>]; however, in some cases, particularly when <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> is the primary opioid being used, the individual may need doses up to 32 mg/day [<a href="#rid16">16-18</a>]. The goal of dose maintenance treatment is to ensure there is no opioid withdrawal, no opioid craving, and no or markedly reduced illicit opioid use.</p><p></p><p class="headingAnchor" id="H1398010525"><span class="h3">Alternative induction methods for specific circumstances</span><span class="headingEndMark"> — </span>In specific circumstances, we use a modified induction protocol, such as low-dose initiation or aggressive <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> induction However, evidence to support their use is limited.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-dose initiation</strong> – Low-dose initiation (also called microdosing) is a method of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> induction that involves frequent administration of small doses (eg, 0.5 to 1 mg) of buprenorphine, which is initiated while the individual is on full agonist [<a href="#rid19">19,20</a>]. Advocates note that with this method, the transition to buprenorphine/naloxone can begin without waiting for signs of withdrawal. Additionally, frequent low dosing avoids precipitation of withdrawal that would otherwise occur with standard doses of buprenorphine in individuals on opioid agonists. However, most of the evidence for the value of this approach is based upon case reports. The use of low-dose initiation can occur in the following clinical scenarios:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High levels of physical dependence (eg, </strong><strong>fentanyl</strong><strong>) </strong>–<strong> </strong>As <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> has become more widely misused, there have been reports of difficulties in achieving successful <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> induction in these patients [<a href="#rid21">21</a>]. This may be related to protracted fentanyl clearance in some patients [<a href="#rid22">22</a>], or due to higher levels of physical dependence. We have used low-dose initiation in these individuals to achieve induction. Other options include waiting longer after the last fentanyl use, giving buprenorphine at longer intervals (&gt;2 hours between doses) or using <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> rather than buprenorphine.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Switching from </strong><strong>methadone</strong> –<strong> </strong>We transition individuals from <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> to <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> using low-dose initiation. With this method, the individual can avoid tapering methadone down prior to beginning buprenorphine [<a href="#rid23">23</a>]. In one study, individuals maintained on methadone 100 mg daily received repeated small doses of <a class="drug drug_general" data-topicid="8788" href="/d/drug information/8788.html" rel="external">buprenorphine-naloxone</a> and did not experience significant precipitated withdrawal symptoms [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individuals who present who are not in withdrawal </strong>–<strong> </strong>In some cases individuals present for induction but have not yet have reached a state of withdrawal. In these cases, we attempt induction with a lower dose of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> (eg, 1 mg or less) given repeatedly at two-hour intervals while monitoring for withdrawal symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aggressive </strong><a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a><strong> induction in emergency department settings </strong>– Aggressive buprenorphine induction may mitigate withdrawal more aggressively and facilitate acceptance of buprenorphine and transition to outpatient treatment. Sublingual buprenorphine (monoproduct formulation) induction using an aggressive dosing approach (4 to 8 mg initially; up to ≤32mg) has been safely used in emergency department settings [<a href="#rid25">25,26</a>].</p><p></p><p class="bulletIndent1">In a retrospective case series of emergency department patients, 391 individuals (579 encounters) with OUD were selected for an aggressive <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> induction (based on history, physical examination, and use of the COWS) [<a href="#rid25">25</a>]. Patients were treated with buprenorphine of up to 32 mg at a rate dependent on severity of withdrawal symptoms and adverse effects. No cases of respiratory depression or sedation or other serious adverse events were reported. These findings may not be generalizable to sublingual formulations other than monoproduct sublingual buprenorphine, and the procedure occurred in a supervised setting (the emergency department).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hospitalized patients</strong> – Hospitalization may provide an opportunity to start individuals with OUD on medication and engage them in care. Initiating MOUD during hospitalization appears to be associated with reduced illicit opioid use and greater adherence to treatment as compared with those who are not started on MOUD [<a href="#rid27">27-29</a>].</p><p></p><p class="bulletIndent1">Our preferred standard initiation regimen for <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> in this circumstance is as follows: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administer <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> 4 mg sublingual</p><p class="bulletIndent2"><span class="glyph">•</span>If ongoing symptoms of withdrawal persist after 45 minutes administer <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> 4 mg sublingual</p><p class="bulletIndent2"><span class="glyph">•</span>Administer additional <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> 4 to 8 mg sublingual every six hours for ongoing withdrawal symptoms</p><p></p><p class="bulletIndent1">Most patients will not require more than 24 mg total daily dose of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> in a 24-hour period, although patients who have been using high potency illicit opioids (eg, <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>) may require up to 32 mg over 24 hours.</p><p></p><p class="headingAnchor" id="H2074308399"><span class="h3">Benefits of using transmucosal buprenorphine</span><span class="headingEndMark"> — </span>Transmucosal <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> improves treatment retention, reduces opioid use, and is associated with decreased mortality in individuals with OUD [<a href="#rid1">1</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of clinical trials, treatment retention was greater at low dose (2 to 6 mg; relative risk 1.5, 95% CI 1.2-1.9), medium doses (7 to 15 mg; relative risk 1.74, 95% CI 1.1-2.7), and high dose (≥16 mg; relative risk 1.82, 95% CI 1.2-2.9) of sublingual <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> compared with placebo [<a href="#rid1">1</a>]. However, in the meta-analysis, only high-dose buprenorphine (≥16 mg) was more effective than placebo in suppressing illicit opioid use (standard mean difference -1.17, 95% CI -1.85 to -0.49). In another trial, individuals treated with buprenorphine (16 mg) or <a class="drug drug_general" data-topicid="8788" href="/d/drug information/8788.html" rel="external">buprenorphine-naloxone</a> (16 mg/4 mg) more frequently had negative urine opioid screening tests compared with those who received placebo (21, 18, and 6 percent respectively) [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of administrative health datasets examined mortality in patients with OUD during periods when they were on <a class="drug drug_general" data-topicid="8788" href="/d/drug information/8788.html" rel="external">buprenorphine-naloxone</a> (13,190 person years of follow-up) and periods when they were off buprenorphine-naloxone (23,712 person years of follow-up) [<a href="#rid31">31</a>]. All-cause mortality was lower when patients were on buprenorphine-naloxone compared with periods when patients were off (standardized mortality ratio 3 versus 11). Mortality due to problematic drug use or accidental drug poisoning was also lower when patients were on <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> rather than off. (See  <a class="medical medical_review" href="/d/html/108803.html" rel="external">"Opioid use disorder: Treatment overview", section on 'Pharmacologic management'</a>.)</p><p></p><p class="headingAnchor" id="H3917035986"><span class="h2">Injectable buprenorphine</span><span class="headingEndMark"> — </span>The long-acting injectable (LAI) formulations of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> are effective for the treatment of OUD [<a href="#rid32">32-34</a>]. We typically use these formulations to address limited adherence, misuse, or diversion of transmucosal buprenorphine. There are two US Food and Drug Administration (FDA)-approved products.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Buprenorphine</strong><strong> XR (Sublocade)</strong> – This is an LAI form of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> that is administered subcutaneously. It is used after a stabilization on transmucosal buprenorphine for a minimum of seven days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initiating </strong><strong>buprenorphine</strong><strong> XR (Sublocade) </strong>– This formulation is administered no more frequently than every 26 days and typically monthly [<a href="#rid35">35</a>]. The procedure for dose stabilization depends upon whether the patient has been on transmucosal <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> for long-term management or for a few days. In either case, transition to Sublocade can occur directly.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients on long-term treatment with transmucosal <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> (ie, months or years), the initial dose of Sublocade for the first month is 300 mg. The dose for the second month dose depends on the total daily dose of buprenorphine previously used. The second dose is 300 mg in individuals who were using greater than 20 mg/day transmucosal buprenorphine or in those with persistent craving or withdrawal symptoms. In individuals who were using 8 to 18 mg transmucosal buprenorphine per day, the second month injection may be 100 mg. In both cases, this is followed by 100 mg monthly maintenance doses.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who have been on transmucosal <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> for a relatively short period (at least seven days, but typically not for weeks), the first month and the second month doses are each 300 mg, and then subsequent doses are 100 mg.</p><p></p><p class="bulletIndent2">While the ultimate recommended maintenance dose is 100 mg, a maintenance dose of 300 mg monthly may be used if the benefits outweigh the risks. For example, if the patient has continued opioid use or symptoms of withdrawal on the 100 mg dose, continuation on the 300 mg monthly dose may be indicated. In addition, situations (eg, extended travel) may arise during maintenance treatment in which a 300 mg dose may be administered to cover a two-month period. Once the situation has passed, the maintenance regimen should revert to 100 mg/month. Patients who are receiving 100 mg/month and then receive a 300 mg injection may experience sedation or other adverse effects due to the higher peak serum concentration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Buprenorphine</strong><strong> XR (Brixadi)</strong> – This is an LAI form of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> that is also administered subcutaneously. Unlike Sublocade, a period of transmucosal stabilization is not necessary [<a href="#rid36">36</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initiating </strong><strong>buprenorphine</strong><strong> XR (Brixadi)</strong> – For persons not on transmucosal <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, a test dose of 4 mg of transmucosal buprenorphine should be given to ensure there is no precipitated withdrawal before giving the first subcutaneous injection. The weekly dose formulation should be used initially. Doses can be administered in the buttock, thigh, or abdomen, but then can be given in the upper arm after four weekly injections. Weekly and then monthly doses vary depending upon whether the patient has been treated with transmucosal buprenorphine, and if they have, their daily dose. The package insert provides guidance on the dosing and should be referenced when starting a patient on this formulation.</p><p></p><p class="bulletIndent2">A clinical trial found the <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> XR (Brixadi) to have similar effect to daily, sublingual buprenorphine in response rates and having urine test results negative for illicit opioids [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefits of </strong><strong>buprenorphine</strong><strong> XR</strong> – Individuals with moderate to severe OUD who are treated with <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> XR are found to have higher abstinence rates than treatment with placebo. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a multisite clinical trial of 202 patients with moderate to severe OUD individuals were randomly assigned to treatment with 300 mg injections monthly for six months versus 300 mg injection monthly for two months, followed by 100 mg injection monthly for four more months versus placebo [<a href="#rid34">34</a>]. Individuals treated with injectable <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> XR maintained higher abstinence rates than those treated with placebo (opioid abstinence rates of 41.3 and 42.7 percent versus 5 percent for 300/300, 300/100, and placebo groups, respectively). The product was well tolerated and had a side effect profile similar to transmucosal buprenorphine.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a separate follow-up observational study, 425 patients with OUD who had received up to 12 months of monthly <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> XR injections as part of a clinical efficacy trial were monitored [<a href="#rid37">37</a>]. Longer durations of treatment were associated with higher rates of sustained abstinence. Additionally, patients had sustained improvements in mood, pain, and health-related quality of life, as well as higher employment rates than at the time of pretrial screening.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk evaluation and mitigation strategy (REMS) program for </strong><strong>buprenorphine</strong><strong> XR</strong> – In the United States, providing either form of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> XR (Sublocade or Brixadi) can only occur through certified health care settings and pharmacies, as a part of each medication’s REMS program. There is a restricted distribution system for buprenorphine XR, and the medication is never given to patients for self-administration. Further information on the REMS program, including enrollment in the program, can be found on <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Frisk-evaluation-and-mitigation-strategies-rems&amp;token=uyQ4GtCAmX4xZ3dpiBd4kEWuBeu2mixXWGnxwcWYS%2Fwcwxo1VWFxfpBz3OdFN7dg%2BGkEuIuOAZq6jU2hG1p8tdXwtCepnSV%2FpTnraw26uuS%2FwDmpsTwMbcG0hJUJV%2F5E&amp;TOPIC_ID=7803" target="_blank">the website</a>.</p><p></p><p class="headingAnchor" id="H3076766508"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Buprenorphine-related deaths in patients on maintenance therapy have occurred primarily when <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> is taken in combination with other substances, especially benzodiazepines and/or alcohol [<a href="#rid38">38,39</a>] and with intravenous misuse of high doses of buprenorphine [<a href="#rid40">40</a>]. Death is caused by oversedation leading to respiratory depression and hypoxia. Buprenorphine has a lower potential for lethal overdose compared with <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>.</p><p>Dental problems including dental caries, abscesses, and damaged teeth, many of which have required extraction may be associated with the use of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> formulations dissolved in the mouth [<a href="#rid41">41-43</a>]. Patients who use oral dissolving buprenorphine should rinse around the teeth and gums with water once the film has completely dissolved. Individuals taking buprenorphine formulations should notify their dentist that they are taking the drug and follow up with routine scheduled dental care. The FDA has issued a safety advisory for this issue and will be mandating a related label change for buprenorphine.</p><p>Other adverse effects of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> include headache, nausea, constipation, pain, and sweating. While these can be distressing to patients, they are not uncommon symptoms experienced while using opioids. Adherence is relatively rarely disturbed by these effects.</p><p class="headingAnchor" id="H1896939956"><span class="h2">Tapering buprenorphine</span><span class="headingEndMark"> — </span>We support the strategy of continuing opioid agonist treatment indefinitely for individuals who have responded to treatment for OUD. However, when the decision is made to discontinue medication for OUD in individuals on <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, we taper over several months if possible.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmucosal </strong><strong>buprenorphine</strong> – We typically reduce the dose by 2 mg every one to two weeks. Based on clinical symptoms, such as the emergence of craving or withdrawal, we may slow down this process as the taper nears the end. If a more rapid taper is necessary (eg, prior to incarceration), the dose can be reduced by 2 mg every one to three days.</p><p></p><p class="bulletIndent1">The relative efficacy of different <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> tapering schedules has not been well studied, but available data suggest that slow, gradual tapers (eg, over months) are more effective and better tolerated than rapid tapers (eg, over days) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1">We include the individual’s primary clinician, program counselor (when the individual is in an opioid treatment program), and other supports (eg, family members with authorization) and employ shared decision-making in planning for taper off of any treatment for OUD. Clinicians without experience tapering a patient off of a maintenance medication would benefit from consultation with a clinician who has such experience.</p><p></p><p class="bulletIndent1">If the individual becomes unstable with recurrent substance use, craving, withdrawal symptoms, or life stressors, the taper should be halted, and they should be encouraged to remain on medication until stability is again achieved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Longer-acting formulation</strong> – Individuals discontinuing <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> XR after sustained use (ie, at least four to six months) may have detectable plasma and urine levels of buprenorphine for 12 months or longer [<a href="#rid45">45</a>]. Tapering off the LAI form could theoretically occur by simply stopping the administrations and allowing the gradual decrease in blood levels to occur over the subsequent weeks.</p><p></p><p class="headingAnchor" id="H3236948077"><span class="h2">Regulation of buprenorphine in United States</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">Buprenorphine</a> is classified as a schedule III controlled substance in the United States. To prescribe buprenorphine for patients with an OUD, clinicians had to apply for a federally required DATA Waiver (X-Waiver). However, in 2023 the Consolidated Appropriations Act removed this requirement. This allows clinicians with schedule III authority on their Drug Enforcement Administration registration to prescribe buprenorphine for opioid use disorder if permitted by applicable state law [<a href="#rid46">46</a>]. Induction may be accomplished in the clinician’s office under observation or at the patient’s home [<a href="#rid47">47</a>]. When on a stable dose, patients may receive a prescription for up to a one-month supply of medication with refills for up to six months, similar to other schedule III controlled substances. There are no longer any limitations in the number of patients any individual clinician can treat.</p><p class="headingAnchor" id="H19508610"><span class="h1">METHADONE: OPIOID AGONIST</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> treatment for opioid use disorder (OUD) is available by prescription and utilizes pharmacy-based dispensing in many countries including Australia, the United Kingdom, and Canada. In the United States, methadone is dispensed through a federally regulated clinic system [<a href="#rid48">48,49</a>]. (See <a class="local">'Regulation of methadone in United States'</a> below.)</p><p><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a>, a long-acting opioid agonist, binds to and occupies mu-opioid receptors, preventing withdrawal symptoms for 24 hours or longer. Methadone reduces craving for opioids, and, by maintaining high levels of opioid tolerance, reduces the euphoric effects of subsequent illicit opioid use. Although individuals treated with methadone are physically dependent upon the medications, they do not typically have the pattern and severity of problematic behaviors associated with use and misuse of heroin or pharmaceutical opioids including <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> and are often able to return to a productive lifestyle [<a href="#rid7">7,8</a>].</p><p class="headingAnchor" id="H2237576805"><span class="h2">Methadone formulations</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> is typically given as a liquid, often diluted with juice or water or artificially colored water. (Each patient receives a full cup of uniformly colored liquid, regardless of the dose of methadone, to reduce anxiety among patients about differences in dose. The dilution and coloring are also intended to reduce the likelihood of a patient injecting “take-home” methadone.) Methadone is available in a tablet form, as well as a dissolvable diskette, and there has been some increase in the use of these forms by opioid treatment programs in the United States during the coronavirus disease 2019 (COVID-19) pandemic.</p><p>While different formulations of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> are available, our preference is to avoid switching formulations if possible. Based upon reports from clinicians and patients, Health Canada issued a safety alert that switching from one liquid formulation of methadone to another liquid formulation at the same dose may elicit withdrawal symptoms, which can lead to nonadherence and problematic substance use [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H4065660434"><span class="h2">Prior to starting methadone</span><span class="headingEndMark"> — </span>Prior to beginning treatment with <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> we assess for potential drug-drug interactions that may help to inform dosing, and the risk of other medical comorbidities relevant to methadone’s use:</p><p class="bulletIndent1"><span class="glyph">●</span>Drug-drug interactions may occur with several commonly used medications (anticonvulsants, antibiotics, antidepressants, antiretrovirals)  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 2</a>). (See <a class="local">'Other adverse effects and considerations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> may be associated with QTc prolongation. For the majority of patients, an electrocardiogram (ECG) prior to beginning methadone is not indicated. For individuals with a history of syncope, arrhythmia, structural heart disease, prolonged QTc, or family history of prolonged QTc, an ECG should be obtained. Additionally, we get an ECG prior to treatment with methadone in individuals already being treated with medications that can prolong QTc.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For QTc interval &gt;450 msec but &lt;500 msec – We start <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> and monitor the ECG 30 days after starting and then annually.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For QTc interval ≥500 msec – We prefer not to start <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> prior to cardiology consultation. We closely weigh the benefits of treatment with methadone with the risks of arrhythmia. If methadone is started, we monitor the ECG 30 days after starting the medication then annually.</p><p></p><p>As there is no compelling research evidence to base a decision on whether to obtain an ECG prior to the start of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> treatment [<a href="#rid51">51-53</a>], we base our decision on clinical experience.</p><p class="headingAnchor" id="H2056648386"><span class="h2">Initial dose and titration</span><span class="headingEndMark"> — </span>The typical initial dose of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> for OUD is 20 to 30 mg in a single dose. The maximum initial dose allowed by most federal regulations or national guidelines is 30 mg [<a href="#rid54">54,55</a>]; however, an additional 10 mg may be administered a few hours later if the individual has significant withdrawal symptoms. The total dose for the first day should not exceed 40 mg. Observation at three hours after the first dose is recommended, if possible, to monitor for signs of toxicity or withdrawal.</p><p>The initial dose of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> maintenance treatment varies based upon the time of the last opioid use, the amount used, and whether the patient has developed a reduction in tolerance to opioids (eg, patients who were recently released from incarceration or hospitalization may have significantly reduced tolerance).</p><p><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> is titrated in 5 to 10 mg increments no more frequently than every two to three days over several weeks until an initial dose in the range of 60 to 80 mg total daily dose is reached. Gradual adjustment allows methadone to reach a pharmacologic steady state to match the patient’s level of opioid tolerance and avoid intoxication or oversedation. Additionally it may help to avoid the rare but possible event of iatrogenic overdose. If excessive opioid agonist effects (eg, sedation) occur, further dose increases are halted. If needed, we titrate beyond 60 to 80 mg per day slowly (eg, 10 mg per week) provided patients do not have intolerable side effects. The rate of titration and eventual dose is based upon the intensity of cravings, the presence of opioid withdrawal symptoms (which are assessed daily) and the cessation of illicit opioid use (as determined by patient reports and urine testing).</p><p class="headingAnchor" id="H3125176062"><span class="h2">Maintenance</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> dosing for maintenance treatment varies [<a href="#rid56">56</a>]. Specifying the dose can be difficult, in part as the dose does not correlate well with blood levels. A relatively low dose of methadone (eg, 20 to 30 mg per day) attenuates acute opioid withdrawal but is usually not as effective as higher doses at suppressing craving and blocking the effects of other opioids, such as heroin. Higher doses (ie, 80 to 100 mg/day) are not overly sedating following the development of tolerance. Doses of up to 150 mg per day are not uncommonly used and higher levels of physical dependence associated with <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> use may require higher doses of methadone.</p><p>Several randomized trials have found that patients on higher doses of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> (80 to 100 mg/day) have higher retention rates and lower illicit use of opioids than lower methadone doses [<a href="#rid6">6,57,58</a>].</p><p>In the United States, patients who have reached a steady maintenance dose, take-home administration of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> is a consideration. Eligibility for take-home doses is usually based on adherence to program requirements for counseling and abstinence from illicit drugs (based on urine toxicology testing), as well as absence of recent criminal activity and capacity to store the take-home doses safely in the home environment.</p><p class="headingAnchor" id="H3369780056"><span class="h2">Benefits of methadone treatment</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> treatment is associated with decreased all-cause mortality from OUD, reduced risk of mortality from overdose (primarily heroin overdose), increased likelihood of remaining in treatment and reduced opioid use compared with those receiving placebo or nonmedication treatment [<a href="#rid4">4,31,59,60</a>].</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 11 studies including 1969 individuals with the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) opioid dependence who were treated with <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> maintenance, individuals treated with methadone were more likely to remain in treatment and to reduce opioid use (relative risk 0.66, 95% CI 0.56-0.78) compared with individuals on placebo or nonmedication treatment [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of administrative health datasets examined mortality in patients with OUD during periods when patients were on <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> (188,113 person years of follow-up) and periods when patients were off methadone (174,431 person years of follow-up) [<a href="#rid31">31</a>]. All-cause mortality was lower when patients were on methadone compared with periods when patients were off (standardized mortality ratio 4.7 versus 9.5). Mortality due to problematic drug use or accidental drug poisoning was also lower when patients were on treatment rather than off. Another observational study suggested a 70 percent reduction in the risk of mortality with methadone maintenance, attributable mainly to prevention of opioid (ie, heroin) overdose [<a href="#rid60">60</a>].</p><p></p><p>Furthermore, <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> maintenance treatment can have beneficial effects beyond the use of opioids. Methadone treatment has been associated with reductions in the spread of human immunodeficiency virus [<a href="#rid61">61-63</a>], and in some studies, with reduced criminal behavior [<a href="#rid4">4,64</a>].</p><p class="headingAnchor" id="H665361939"><span class="h2">Tapering off of methadone</span><span class="headingEndMark"> — </span>We support the strategy of continuing opioid agonist treatment indefinitely for individuals who have responded to treatment for OUD. However, when the decision is made to discontinue medication for OUD in individuals on <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, we taper slowly (over months) and gradually (eg, dose decreases of up to 5 mg/week with smaller dose decreases as the taper nears the end). We allow and encourage the patient to pause the taper if instability such as withdrawal symptoms occurs.</p><p class="headingAnchor" id="H2257238438"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Adverse effects of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> therapy include constipation, drowsiness, diaphoresis, peripheral edema, and rarely cardiac arrhythmia [<a href="#rid65">65,66</a>].</p><p class="headingAnchor" id="H3414490395"><span class="h3">Prolonged QTc and cardiac arrhythmias</span><span class="headingEndMark"> — </span>We check ECG 30 days after starting <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> and then annually thereafter in individuals at risk for prolonged QTc. This includes individuals with a history of syncope, arrhythmia, structural heart disease, prolonged QTc (&gt;450 msec), family history of prolonged QTc or in individuals on other medications that can prolong QTc. Our response to the ECG findings are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For QTc interval &gt;450 msec but &lt;500 msec – We continue treatment and monitor the ECG annually.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For QTc interval ≥500 msec – We prefer to discontinue <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>; however, we closely weigh the benefits of treatment with methadone with the risks of arrhythmia. We often lower the dose of methadone (if clinically reasonable) while addressing other causative factors such as hypokalemia or other medications that may cause prolonged QTc. However, we typically consult with a cardiologist prior to making medication adjustments.</p><p></p><p>Studies have noted a significant but weak relationship between the <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> dose and the degree of QTc prolongation at doses of up to 300 mg/day [<a href="#rid67">67-70</a>]. Additionally, methadone use in both therapeutic dose and overdose has been associated with QTc interval prolongation and torsades de pointes, which in some cases has been fatal [<a href="#rid71">71</a>]. However, while the risk of QTc prolongation in methadone treated patients is controversial, concern regarding the proarrhythmic potential of methadone prompted a clinician safety alert from the US Food and Drug Administration.</p><p>Some research suggests that substitution of (R,S)-methadone with (R)-methadone reduces the methadone-induced prolonged QTc interval among individuals with OUD [<a href="#rid72">72</a>]. Further work is needed to confirm this finding. The (R)-methadone formulation is available in the European Union and is widely used in Germany, but is not available for clinical use in the United States. The use of a pure (R)-formulation of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> also results in lower effective doses, but its cost is up to 20 percent higher than the racemic formulation [<a href="#rid73">73</a>].</p><p>The associated table lists causes of prolonged QTc  (<a class="graphic graphic_table graphicRef57431" href="/d/graphic/57431.html" rel="external">table 3</a>). Drug-induced QTc prolongation is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p class="headingAnchor" id="H2072688232"><span class="h3">Other adverse effects and considerations</span><span class="headingEndMark"> — </span>Other adverse effects and drug-drug interactions include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperalgesia</strong> – Chronic use of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> and other opioid agonists may result in an increased sensitivity to pain, which may develop within a month of initiating chronic opioid therapy [<a href="#rid74">74-76</a>]. A study of patients in methadone treatment programs found chronic severe pain was reported by 37 percent of the patients, and 65 percent of those with pain experienced a significant impact on physical and psychosocial functioning [<a href="#rid76">76</a>]. Patients in methadone treatment may have a history of physical trauma resulting in chronic pain, but may also have increased sensitivity to pain related to chronic opioid use [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overdose</strong> – As a full agonist, <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> has a greater potential for lethal overdose compared with <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, a partial mu-opioid agonist. Death during induction into methadone maintenance treatment has been reported in a series of cases from New South Wales, Australia [<a href="#rid78">78-80</a>]. The overall mortality rate during methadone maintenance induction was 7.1 deaths per 10,000 inductions [<a href="#rid80">80</a>]. Concurrent benzodiazepine use was a significant risk factor contributing to likelihood of death both in methadone maintenance patients and in patients taking methadone for chronic pain [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduced libido and erectile dysfunction</strong> – Reduced libido and erectile dysfunction are common among heroin users and those in treatment for OUD. <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> use is believed to contribute to erectile dysfunction, possibly through reduction in serum testosterone levels; however, psychological and social factors are also associated with erectile dysfunction [<a href="#rid82">82,83</a>]. These other factors should be considered before attributing erectile dysfunction solely to methadone treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions and metabolism </strong>– <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> has a number of drug interactions based on metabolism by the cytochrome P450 isoenzyme system, specifically CYP 3A4, 2D6, and 2B6  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 2</a>) [<a href="#rid84">84,85</a>]. Starting or stopping medications that interact with these enzymes can affect serum methadone levels. This may result in opioid withdrawal or intoxication.</p><p></p><p class="bulletIndent1">Daily <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> dose may need adjustment to prevent complications from these interactions. For example, individuals who concurrently take benzodiazepines or use alcohol may be more likely to become sedated from methadone and should be evaluated for the risk of respiratory depression. In these cases, dose of medications should be adjusted accordingly.</p><p></p><p class="headingAnchor" id="H1811207820"><span class="h2">Regulation of methadone in United States</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> is regulated in many countries including the United States, where it is classified as a schedule II drug. Many of the regulations on methadone’s use are aimed at preventing diversion of medication and reducing the risk of overdose. Only licensed opioid treatment programs or licensed inpatient hospital units in the United States are permitted to order and dispense methadone for withdrawal or long-term treatment of an OUD [<a href="#rid86">86</a>]. Exceptions to this restriction include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients already receiving <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> from a licensed program may continue to receive the medication during inpatient hospitalization to treat OUD or other conditions, such as pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any clinician or other licensed prescriber may administer <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> (or any other opioid) to treat a patient with acute opioid withdrawal for up to three days while arranging for more definitive treatment, provided they follow federal regulations (21 CFR 1306.07(b)). The intent is to relieve suffering and prevent withdrawal that would complicate the primary medical or surgical condition. While methadone may be administered to a patient during the 72-hour period, it may not be dispensed or prescribed for unsupervised use.</p><p></p><p>To be eligible for <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> maintenance in the United States under federal guidelines, a prospective patient must have [<a href="#rid86">86</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Documentation of the presence of an OUD for at least one year of continuous use. Exceptions to this criterion include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who have been on <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> maintenance within the past two years do not need to demonstrate current physical dependence or a current OUD if the program clinician documents a likelihood of an imminent relapse to opioid use.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients recently released from incarceration or hospitalization do not need to show current physiologic dependence or OUD but are required to have a history of an OUD and have a clinician document a likelihood of relapse to opioid use and physiologic dependence.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pregnant women are eligible for <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> maintenance even if an OUD has been present for less than one year.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age 18 years or older – Younger individuals are eligible for treatment with the consent of a parent, guardian, or designated responsible adult if they have current opioid physical dependence and have at least two previous attempts at detoxification or psychosocial substance abuse treatment.</p><p></p><p>Licensed United States outpatient treatment programs are required to provide counseling and social services in addition to <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>. Patients are required to attend individual counseling as clinically indicated. (See  <a class="medical medical_review" href="/d/html/99647.html" rel="external">"Opioid use disorder: Psychosocial management"</a>.)</p><p>In addition to federal regulations, many states in the United States have imposed additional restrictions on <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> for use in the treatment of an OUD.</p><p class="headingAnchor" id="H275445708"><span class="h2">Switching between agonist treatments</span><span class="headingEndMark"> — </span>Individuals with physiologic opioid dependence who are transitioned directly from <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> maintenance to <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> may experience acute precipitated opioid withdrawal syndrome [<a href="#rid87">87,88</a>]. In these cases, we often use low-dose buprenorphine induction. (See <a class="local">'Alternative induction methods for specific circumstances'</a> above.)</p><p>For individuals with physiologic opioid dependence who have a poor response or unacceptable side effects to <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, this medication can be discontinued and <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> started immediately.</p><p class="headingAnchor" id="H4173347983"><span class="h1">NALTREXONE: OPIOID ANTAGONIST</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">Naltrexone</a>, an opioid antagonist, blocks the effects of opioids if they are used, thus preventing the user from experiencing opioid intoxication or physiologic dependence with subsequent use and thus reinforces abstinence.</p><p class="headingAnchor" id="H3769714776"><span class="h2">Prior to treatment with opioid antagonist</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">Naltrexone</a> should be used only after completion of a medically supervised withdrawal from opioids because it can precipitate immediate withdrawal symptoms. Initiation of naltrexone should be medically supervised.</p><p>In some cases, a <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> challenge test is useful to ensure that the patient has completed withdrawal from opioids and is no longer physically dependent on this class of drugs. If there are reasons to suspect that the person has not had a sufficient period of opioid abstinence (eg, an outpatient who has attempted to abstain from opioids on their own for several days), then a naloxone challenge test should be undertaken.</p><p>However, in our experience most patients are forthright about their use when it is explained that there is a risk of precipitated withdrawal with <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> dosing if they have continued opioid use. When needed, the <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> challenge test is done as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>The patient should be totally free of spontaneous opioid withdrawal signs and symptoms at the start of the <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> challenge session.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Baseline vital signs are obtained, and <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> is then administered parenterally (subcutaneously, intramuscularly [IM], or intravenously) up to a total dose of 0.8 mg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient is observed for up to one hour, and a validated measure for assessing opioid withdrawal, such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnida.nih.gov%2Fsites%2Fdefault%2Ffiles%2FClinicalOpiateWithdrawalScale.pdf&amp;token=nJNeVBJPxO9PvYcOzt5SbPYKMNdIvUrzFnw4xvcsEliSlpRLBj7qcvzLxtew4P71OU0PSho%2Bmddv1C2VRZHHh8VW8UTfbP84pTeOD9AU1c0%3D&amp;TOPIC_ID=7803" target="_blank">Clinical Opiate Withdrawal Scale</a> can be helpful to use.</p><p></p><p>If any symptoms or signs of opioid withdrawal emerge, or if pulse rate or blood pressure increases, administration of <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> should be postponed for another 24 hours. Since <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> has a short half-life, any withdrawal precipitated by naloxone typically will resolve within one to two hours of administration or less.</p><p class="headingAnchor" id="H3057268677"><span class="h2">Long-acting injectable naltrexone</span><span class="headingEndMark"> — </span>Our preference is to treat opioid use disorder (OUD) with long-acting injectable (LAI; or extended-release) <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> rather than oral naltrexone. LAI naltrexone is given every four weeks by deep IM injection in the gluteal muscle at a set dose of 380 mg per injection. It should be administered in alternating buttocks each month. The medication is started 7 to 10 days after last opioid use unless a <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> challenge test is conducted and confirms the safety of starting oral naltrexone sooner.</p><p>The American Society of Addiction Medicine has suggested that in cases of breakthrough cravings LAI <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> may be given every three weeks. However, there are currently no studies to support this more frequent dosing, and this is not our routine practice.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefits of LAI </strong><strong>naltrexone</strong> – In randomized trials, LAI <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> is more effective than placebo for opioid dependence [<a href="#rid2">2,89-91</a>]. However, the transition to LAI naltrexone may be a challenge for some individuals; additionally, trials of LAI naltrexone have been limited by high dropout rates [<a href="#rid2">2,89</a>]. For example:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a trial, 250 individuals with DSM-IV opioid dependence were randomized to receive 24 weeks of injectable depot formulation of <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> versus placebo [<a href="#rid2">2</a>]. The median proportion of weeks of confirmed abstinence was greater in the actively treated group compared with the placebo group (90 versus 35 percent). However, these findings exclude 47 percent of the patients who did not complete the study.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a trial, 308 individuals in the criminal justice system were randomly assigned to LAI <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> versus treatment as usual (brief counseling and referral to community treatment program) for a period of 24 weeks [<a href="#rid3">3</a>]. Individuals in the treatment group had a longer median time to relapse (10.5 versus 5 weeks), a lower rate of relapse (43 versus 64 percent), and higher rate of opioid negative urine samples (74 versus 56 percent) versus control group. However, at 78-week follow-up, rates of opioid-negative urine samples were equal (46 percent in each group).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Injection site reaction</strong> – <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">Naltrexone</a> via IM injection may cause injection site reaction consisting of pain, tenderness, and swelling at the injection site. In some cases, abscess, cellulitis, and necrosis have been reported. While treatment for such reactions is generally supportive, if symptoms appear to be worsening after seven days, further evaluation with a surgical specialist is warranted.</p><p></p><p class="headingAnchor" id="H2742275152"><span class="h2">Oral naltrexone</span><span class="headingEndMark"> — </span>We typically begin oral <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> at 25 mg per day for the first two to three days before increasing to 50 mg per day. The medication is started 7 to 10 days after last opioid use unless a <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> challenge test is conducted and confirms the safety of starting oral naltrexone sooner. (See <a class="local">'Prior to treatment with opioid antagonist'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefits of oral </strong><strong>naltrexone</strong> – Efficacy of oral <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> for sustained abstinence in treatment of individuals with opioid dependence is limited. A meta-analysis of 1158 participants in 13 randomized trials compared oral naltrexone maintenance treatment with either placebo or no medication for opioid dependence [<a href="#rid92">92</a>]. Primary outcomes such as sustained abstinence were similar between active and control groups. The findings from these trials were limited by poor adherence and high dropout rates. However, oral naltrexone was more effective than placebo in sustaining abstinence in three trials where patients were monitored for daily adherence by a close relative [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects and subsequent considerations</strong> – Oral <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> has few side effects or adverse effects. Occasionally patients will report nausea, headache, dizziness, or fatigue. More severe adverse effects include liver damage, but this is very rare (seen with supratherapeutic doses) and has always resolved with discontinuation of naltrexone.</p><p></p><p class="bulletIndent1">Patients who discontinue antagonist therapy and resume opioid use should be made aware of the risks associated with an opioid overdose and especially the increased risk of death. This is due to the loss of tolerance to opioids and a resulting misjudgment of dose at the time of relapse [<a href="#rid93">93</a>].</p><p></p><p class="headingAnchor" id="H1324092815"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113643.html" rel="external">"Society guideline links: Opioid use disorder and withdrawal"</a>.)</p><p class="headingAnchor" id="H19508923"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16997.html" rel="external">"Patient education: Prescription drug misuse (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/95131.html" rel="external">"Patient education: Opioid use disorder (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19508929"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach </strong>– We prefer to treat all individuals with opioid use disorder (OUD) with medication for OUD (MOUD) and psychotherapy. MOUD reinforces abstinence and improves treatment retention. Our approach to selecting treatments including medication and psychotherapy is discussed elsewhere  (<a class="graphic graphic_algorithm graphicRef134961" href="/d/graphic/134961.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/108803.html" rel="external">"Opioid use disorder: Treatment overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioid agonists</strong> – Opioid agonists (eg, <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> and <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>) suppress craving and withdrawal symptoms while blocking the acute effects of other opioids. Although individuals treated with opioid agonists are physically dependent upon the medications, they do not typically have the severity of problematic behaviors associated with illicit use or misuse of opioids. (See <a class="local">'Buprenorphine: Opioid agonist'</a> above and <a class="local">'Methadone: Opioid agonist'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Buprenorphine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">Buprenorphine</a> is most often given transmucosally as a combination preparation with <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> to prevent diversion of the product. It is also available as a longer-acting injectable formulation. In most formulations, the dose depends on the duration and dose of prior transmucosal use. (See <a class="local">'Transmucosal formulations'</a> above and <a class="local">'Injectable buprenorphine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most individuals, we use a standard induction to initiate transmucosal <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>. We wait until the individual shows signs of early withdrawal and then start 4 mg of buprenorphine and gradually titrate up until withdrawal symptoms have resolved. (See <a class="local">'Standard induction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals who present for induction without withdrawal symptoms, who have high levels of physical dependence, or who are transitioning from <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, we suggest a low-dose protocol, in which a lower dose than that used for standard induction is administered more frequently (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Alternative induction methods for specific circumstances'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methadone</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a>, a long-acting opioid agonist, binds to mu-opioid receptors, preventing withdrawal symptoms for 24 hours or more. (See <a class="local">'Methadone: Opioid agonist'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the United States, administration of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> takes places in an opioid treatment program. Take-home doses of methadone may be available based on program requirements. (See <a class="local">'Regulation of methadone in United States'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> carries a risk for lethal overdose. Other adverse effects include QTc prolongation, drug-drug interactions, and hyperalgesia. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioid antagonists </strong>– <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">Naltrexone</a>, an opioid antagonist, prevents the user from experiencing opioid intoxication or physiologic dependence, thereby reinforcing abstinence. Naltrexone can precipitate withdrawal in individuals with physiologic opioid dependence and should be used only after completion of medically supervised withdrawal. (See <a class="local">'Naltrexone: Opioid antagonist'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">Naltrexone</a> is available in oral and long-acting injectable (LAI) formulation. We typically use the LAI naltrexone formulation when addressing limited adherence. (See <a class="local">'Long-acting injectable naltrexone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">Naltrexone</a> LAI may cause an injection site reaction (ie, pain, swelling, abscess, cellulitis, necrosis). Treatment for injection site reactions is generally supportive; however, worsening symptoms after seven days warrants evaluation with a surgical specialist. (See <a class="local">'Naltrexone: Opioid antagonist'</a> above.)</p><p></p><p class="headingAnchor" id="H3751053436"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael Weaver, MD and John Hopper, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; :CD002207.</a></li><li><a class="nounderline abstract_t">Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011; 377:1506.</a></li><li><a class="nounderline abstract_t">Lee JD, Friedmann PD, Kinlock TW, et al. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med 2016; 374:1232.</a></li><li><a class="nounderline abstract_t">Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; :CD002209.</a></li><li><a class="nounderline abstract_t">Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003; 361:662.</a></li><li><a class="nounderline abstract_t">Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343:1290.</a></li><li><a class="nounderline abstract_t">Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Methadone dose and treatment outcome. Drug Alcohol Depend 1993; 33:105.</a></li><li><a class="nounderline abstract_t">Hauri-Bionda R, Bär W, Friedrich-Koch A. [Driving fitness/driving capacity of patients treated with methadone]. Schweiz Med Wochenschr 1998; 128:1538.</a></li><li><a class="nounderline abstract_t">Chilcoat HD, Amick HR, Sherwood MR, Dunn KE. Buprenorphine in the United States: Motives for abuse, misuse, and diversion. J Subst Abuse Treat 2019; 104:148.</a></li><li><a class="nounderline abstract_t">Buprenorphine: an alternative to methadone. Med Lett Drugs Ther 2003; 45:13.</a></li><li><a class="nounderline abstract_t">Preston KL, Bigelow GE, Liebson IA. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend 1990; 25:27.</a></li><li><a class="nounderline abstract_t">Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003; 70:S39.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP). Series 63 Publication No. PEP2, Substance Abuse and Mental Health Services Administration; Department of Health and Human Services, Rockville, MD 2021.</li><li><a class="nounderline abstract_t">Dematteis M, Auriacombe M, D'Agnone O, et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother 2017; 18:1987.</a></li><li><a class="nounderline abstract_t">Soeffing JM, Martin LD, Fingerhood MI, et al. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat 2009; 37:426.</a></li><li><a class="nounderline abstract_t">Fareed A, Vayalapalli S, Casarella J, Drexler K. Treatment outcome for flexible dosing buprenorphine maintenance treatment. Am J Drug Alcohol Abuse 2012; 38:155.</a></li><li><a class="nounderline abstract_t">Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend 2014; 144:1.</a></li><li><a class="nounderline abstract_t">Chambers LC, Hallowell BD, Zullo AR, et al. Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl. JAMA Netw Open 2023; 6:e2334540.</a></li><li><a class="nounderline abstract_t">Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of Buprenorphine/Naloxone: A Review of the Literature. Am J Addict 2021; 30:305.</a></li><li><a class="nounderline abstract_t">Schult RF, Maynard KM, Corvelli JM, et al. Low-dose Initiation of Buprenorphine in Hospitalized Patients on Full Agonist Opioid Therapy: A Retrospective Observational Study. J Addict Med 2023; 17:685.</a></li><li><a class="nounderline abstract_t">Shearer D, Young S, Fairbairn N, Brar R. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series. Drug Alcohol Rev 2022; 41:444.</a></li><li><a class="nounderline abstract_t">Huhn AS, Hobelmann JG, Oyler GA, Strain EC. Protracted renal clearance of fentanyl in persons with opioid use disorder. Drug Alcohol Depend 2020; 214:108147.</a></li><li class="breakAll">McNicholas L. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. US Department of Health and Human Services, Rockville, MD 2004.</li><li><a class="nounderline abstract_t">Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend 2007; 90:261.</a></li><li><a class="nounderline abstract_t">Herring AA, Vosooghi AA, Luftig J, et al. High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. JAMA Netw Open 2021; 4:e2117128.</a></li><li><a class="nounderline abstract_t">Snyder H, Chau B, Kalmin MM, et al. High-Dose Buprenorphine Initiation in the Emergency Department Among Patients Using Fentanyl and Other Opioids. JAMA Netw Open 2023; 6:e231572.</a></li><li><a class="nounderline abstract_t">Christian N, Bottner R, Baysinger A, et al. Hospital Buprenorphine Program for Opioid Use Disorder Is Associated With Increased Inpatient and Outpatient Addiction Treatment. J Hosp Med 2021; 16:345.</a></li><li><a class="nounderline abstract_t">Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med 2014; 174:1369.</a></li><li><a class="nounderline abstract_t">Noam KR, Schmutte TJ, Pirard S, et al. Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use. J Addict Med 2023; 17:e199.</a></li><li><a class="nounderline abstract_t">Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349:949.</a></li><li><a class="nounderline abstract_t">Pearce LA, Min JE, Piske M, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ 2020; 368:m772.</a></li><li><a class="nounderline abstract_t">Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA 2010; 304:1576.</a></li><li><a class="nounderline abstract_t">Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial. JAMA Intern Med 2018; 178:764.</a></li><li><a class="nounderline abstract_t">Haight BR, Learned SM, Laffont CM, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019; 393:778.</a></li><li class="breakAll">Prescribing information for Sublocade. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209819s012lbl.pdf (Accessed on March 25, 2020).</li><li class="breakAll">Brixadi prescribing information. US Food and Drug Administration. https://www.brixadi.com/pdfs/brixadi-prescribing-information.pdf (Accessed on August 18, 2023).</li><li><a class="nounderline abstract_t">Ling W, Nadipelli VR, Aldridge AP, et al. Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study. J Addict Med 2020; 14:e233.</a></li><li><a class="nounderline abstract_t">Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998; 22:430.</a></li><li><a class="nounderline abstract_t">Park TW, Larochelle MR, Saitz R, et al. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine. Addiction 2020; 115:924.</a></li><li><a class="nounderline abstract_t">Byrne A. Reducing deaths among drug misusers. Standard of care in Britain was not addressed. BMJ 2001; 323:513.</a></li><li class="breakAll">FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain. US Food and Drug Administration. Available at: https://www.fda.gov/media/155352/download (Accessed on January 21, 2022).</li><li><a class="nounderline abstract_t">Suzuki J, Mittal L, Woo SB. Sublingual buprenorphine and dental problems: a case series. Prim Care Companion CNS Disord 2013; 15.</a></li><li><a class="nounderline abstract_t">Etminan M, Rezaeianzadeh R, Kezouh A, Aminzadeh K. Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease. JAMA 2022; 328:2269.</a></li><li><a class="nounderline abstract_t">Senay EC, Dorus W, Goldberg F, Thornton W. Withdrawal from methadone maintenance. Rate of withdrawal and expectation. Arch Gen Psychiatry 1977; 34:361.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209819s018lbl.pdf (Accessed on July 13, 2021).</li><li class="breakAll">Substance Abuse anda Mental Health Services Administration. Removal of DATA Waiver (X-Waiver) Requirement. https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement (Accessed on February 07, 2023).</li><li><a class="nounderline abstract_t">Gunderson EW, Wang XQ, Fiellin DA, et al. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav 2010; 35:537.</a></li><li><a class="nounderline abstract_t">Samet JH, Botticelli M, Bharel M. Methadone in Primary Care - One Small Step for Congress, One Giant Leap for Addiction Treatment. N Engl J Med 2018; 379:7.</a></li><li class="breakAll">Publications Office of the European Union. Guidelines for the treatment of drug dependence: A European perspective: EMCDDA Selected issues. Available at: https://op.europa.eu/en/publication-detail/-/publication/77067ee3-6700-4be2-a51f-8b24b6250909/language-en (Accessed on April 11, 2022).</li><li class="breakAll">Methadone Treatment of Opioid Dependence and Potential Differences in Product Effect. https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72675a-eng.php (Accessed on April 01, 2020).</li><li><a class="nounderline abstract_t">Byrne A. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Ann Intern Med 2009; 151:216; author reply 218.</a></li><li><a class="nounderline abstract_t">Cohen SP, Mao J. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Ann Intern Med 2009; 151:216.</a></li><li><a class="nounderline abstract_t">Pani PP, Trogu E, Maremmani I, Pacini M. QTc interval screening for cardiac risk in methadone treatment of opioid dependence. Cochrane Database Syst Rev 2013; :CD008939.</a></li><li class="breakAll">National Guidelines for Medication-Assisted Treatment of Opioid Dependence. Australian Government Department of Health. Available at: https://www.health.gov.au/sites/default/files/national-guidelines-for-medication-assisted-treatment-of-opioid-dependence.pdf (Accessed on April 10, 2022).</li><li><a class="nounderline abstract_t">Bruneau J, Ahamad K, Goyer MÈ, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ 2018; 190:E247.</a></li><li class="breakAll">Strain EC, Stoller KB. Methadone and buprenorphine maintenance. In: Textbook of Substance Abuse Treatment, 5th ed, Galanter M, Kleber HD, Brady KT (Eds), American Psychiatric Publishing, Washington DC 2015. p.311.</li><li><a class="nounderline abstract_t">Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999; 281:1000.</a></li><li><a class="nounderline abstract_t">Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; :CD002208.</a></li><li><a class="nounderline abstract_t">Bell J, Zador D. A risk-benefit analysis of methadone maintenance treatment. Drug Saf 2000; 22:179.</a></li><li><a class="nounderline abstract_t">Desmond, DP, Maddux, JF. Deaths among heroin users in and out of methadone treatment. J Maint Addict 2000; 1:45.</a></li><li><a class="nounderline abstract_t">Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav 1988; 29:214.</a></li><li><a class="nounderline abstract_t">Novick DM, Joseph H, Croxson TS, et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med 1990; 150:97.</a></li><li><a class="nounderline abstract_t">Gowing LR, Farrell M, Bornemann R, et al. Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 2006; 21:193.</a></li><li><a class="nounderline abstract_t">Nurco DN, Ball JC, Shaffer JW, Hanlon TE. The criminality of narcotic addicts. J Nerv Ment Dis 1985; 173:94.</a></li><li><a class="nounderline abstract_t">O'Conor LM, Woody G, Yeh HS, et al. Methadone and edema. J Subst Abuse Treat 1991; 8:153.</a></li><li><a class="nounderline abstract_t">Kleber HD. Treatment of narcotic addicts. Psychiatr Med 1985; 3:389.</a></li><li><a class="nounderline abstract_t">Ehret GB, Voide C, Gex-Fabry M, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006; 166:1280.</a></li><li><a class="nounderline abstract_t">Martell BA, Arnsten JH, Ray B, Gourevitch MN. The impact of methadone induction on cardiac conduction in opiate users. Ann Intern Med 2003; 139:154.</a></li><li><a class="nounderline abstract_t">Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005; 95:915.</a></li><li><a class="nounderline abstract_t">Peles E, Bodner G, Kreek MJ, et al. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction 2007; 102:289.</a></li><li><a class="nounderline abstract_t">Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005; 14:747.</a></li><li><a class="nounderline abstract_t">Ansermot N, Albayrak O, Schläpfer J, et al. Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval. Arch Intern Med 2010; 170:529.</a></li><li><a class="nounderline abstract_t">McCance-Katz EF. (R)-methadone versus racemic methadone: what is best for patient care? Addiction 2011; 106:687.</a></li><li><a class="nounderline abstract_t">Pud D, Cohen D, Lawental E, Eisenberg E. Opioids and abnormal pain perception: New evidence from a study of chronic opioid addicts and healthy subjects. Drug Alcohol Depend 2006; 82:218.</a></li><li><a class="nounderline abstract_t">Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006; 7:43.</a></li><li><a class="nounderline abstract_t">Rosenblum A, Joseph H, Fong C, et al. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003; 289:2370.</a></li><li><a class="nounderline abstract_t">Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 2001; 63:139.</a></li><li><a class="nounderline abstract_t">Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust 1999; 170:104.</a></li><li><a class="nounderline abstract_t">Zador DA, Sunjic SD. Methadone-related deaths and mortality rate during induction into methadone maintenance, New South Wales, 1996. Drug Alcohol Rev 2002; 21:131.</a></li><li><a class="nounderline abstract_t">Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction 2000; 95:77.</a></li><li><a class="nounderline abstract_t">Caplehorn JR, Drummer OH. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health 2002; 26:358.</a></li><li><a class="nounderline abstract_t">Brown R, Balousek S, Mundt M, Fleming M. Methadone maintenance and male sexual dysfunction. J Addict Dis 2005; 24:91.</a></li><li><a class="nounderline abstract_t">Quaglio G, Lugoboni F, Pattaro C, et al. Erectile dysfunction in male heroin users, receiving methadone and buprenorphine maintenance treatment. Drug Alcohol Depend 2008; 94:12.</a></li><li><a class="nounderline abstract_t">Kharasch ED. Current Concepts in Methadone Metabolism and Transport. Clin Pharmacol Drug Dev 2017; 6:125.</a></li><li><a class="nounderline abstract_t">Dinis-Oliveira RJ. Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response. Drug Metab Rev 2016; 48:568.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration. Federal Guidelines for Opioid Treatment Programs. HHS Publication No. (SMA) XX-XXX, Health and Human Services, Rockville, MD 2015.</li><li><a class="nounderline abstract_t">Strain EC, Preston KL, Liebson IA, Bigelow GE. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther 1995; 272:628.</a></li><li><a class="nounderline abstract_t">Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003; 70:S13.</a></li><li><a class="nounderline abstract_t">Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63:210.</a></li><li><a class="nounderline abstract_t">Tiihonen J, Krupitsky E, Verbitskaya E, et al. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry 2012; 169:531.</a></li><li><a class="nounderline abstract_t">Sullivan M, Bisaga A, Pavlicova M, et al. Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine. Am J Psychiatry 2017; 174:459.</a></li><li><a class="nounderline abstract_t">Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011; :CD001333.</a></li><li><a class="nounderline abstract_t">Strang J, McCambridge J, Best D, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003; 326:959.</a></li></ol></div><div id="topicVersionRevision">Topic 7803 Version 74.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24500948" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21529928" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27028913" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588333" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12606177" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11058673" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8261875" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Methadone dose and treatment outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9816613" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : [Driving fitness/driving capacity of patients treated with methadone].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31370979" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Buprenorphine in the United States: Motives for abuse, misuse, and diversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12592214" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Buprenorphine: an alternative to methadone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2323306" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effects of sublingually given naloxone in opioid-dependent human volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738349" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pharmacokinetics of the combination tablet of buprenorphine and naloxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738349" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pharmacokinetics of the combination tablet of buprenorphine and naloxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29183228" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19553061" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22175698" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment outcome for flexible dosing buprenorphine maintenance treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25179217" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37721749" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33378137" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Microinduction of Buprenorphine/Naloxone: A Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37934532" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Low-dose Initiation of Buprenorphine in Hospitalized Patients on Full Agonist Opioid Therapy: A Retrospective Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34647379" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32650192" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Protracted renal clearance of fentanyl in persons with opioid use disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32650192" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Protracted renal clearance of fentanyl in persons with opioid use disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17517480" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34264326" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36867410" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : High-Dose Buprenorphine Initiation in the Emergency Department Among Patients Using Fentanyl and Other Opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34129485" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hospital Buprenorphine Program for Opioid Use Disorder Is Associated With Increased Inpatient and Outpatient Addiction Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25090173" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37267183" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12954743" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32234712" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20940383" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29799968" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30792007" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30792007" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30792007" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32187112" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9788517" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31916306" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560138" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Reducing deaths among drug misusers. Standard of care in Britain was not addressed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560138" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Reducing deaths among drug misusers. Standard of care in Britain was not addressed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24511440" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sublingual buprenorphine and dental problems: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36511932" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/843188" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Withdrawal from methadone maintenance. Rate of withdrawal and expectation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/843188" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Withdrawal from methadone maintenance. Rate of withdrawal and expectation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/843188" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Withdrawal from methadone maintenance. Rate of withdrawal and expectation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20106601" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29972744" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Methadone in Primary Care - One Small Step for Congress, One Giant Leap for Addiction Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29972744" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Methadone in Primary Care - One Small Step for Congress, One Giant Leap for Addiction Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29972744" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Methadone in Primary Care - One Small Step for Congress, One Giant Leap for Addiction Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19652191" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Concerns about consensus guidelines for QTc interval screening in methadone treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19652190" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Concerns about consensus guidelines for QTc interval screening in methadone treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23787716" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : QTc interval screening for cardiac risk in methadone treatment of opioid dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23787716" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : QTc interval screening for cardiac risk in methadone treatment of opioid dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29507156" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Management of opioid use disorders: a national clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29507156" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Management of opioid use disorders: a national clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086434" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12917925" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Methadone maintenance at different dosages for opioid dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10738842" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A risk-benefit analysis of methadone maintenance treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Deaths among heroin users in and out of methadone treatment</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3241064" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Reducing the risk of AIDS through methadone maintenance treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2297301" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336624" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3881559" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The criminality of narcotic addicts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1960766" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Methadone and edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3916682" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Treatment of narcotic addicts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801510" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12859171" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The impact of methadone induction on cardiac conduction in opiate users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781034" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Impact of methadone treatment on cardiac repolarization and conduction in opioid users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222284" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15918160" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308640" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21371149" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : (R)-methadone versus racemic methadone: what is best for patient care?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16229972" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Opioids and abnormal pain perception: New evidence from a study of chronic opioid addicts and healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16414554" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12746360" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11376918" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10065120" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Mortality associated with New South Wales methadone programs in 1994: lives lost and saved.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12188991" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Methadone-related deaths and mortality rate during induction into methadone maintenance, New South Wales, 1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10723832" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12233958" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15784526" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Methadone maintenance and male sexual dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18083312" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Erectile dysfunction in male heroin users, receiving methadone and buprenorphine maintenance treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28263461" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Current Concepts in Methadone Metabolism and Transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27320437" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27320437" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7853176" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738347" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461865" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22764364" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28068780" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21491383" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Oral naltrexone maintenance treatment for opioid dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12727768" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
